Tomasello is a Renowned Industry Expert Responsible for the Commercialization of Revolutionary, Multi-Billion Dollar Products in Hematology-Oncology RA’ANANA, Israel and NEW YORK , July 10, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company
RA’ANANA, Israel and NEW YORK , June 13, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie Belldegrun, MD, FACS, UroGen’s
RA’ANANA, Israel , and NEW YORK , June 05, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced that Stephen Mullennix , UroGen’s Chief Operating Officer, will
RA’ANANA, Israel and NEW YORK , May 29, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur , Chief Executive
Interim Results Showed Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade UTUC CRs to Date Remain Durable at Three, Six and Nine-Month Follow-Up RA’ANANA, Israel and NEW YORK , May 21, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical
Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA) Annual Meeting on May 21, 2018 Submission of UGN-101 New Drug Application (NDA) to the U.S.
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK , May 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2018 financial results on Tuesday, May 15, 2018 , prior to the open of the market.
RA’ANANA, Israel and NEW YORK , April 24, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that members of management and the
RA’ANANA, Israel and NEW YORK , April 03, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a new data presentation from an interim
Presentation of MitoGel™ Interim Analysis from OLYMPUS Pivotal Trial in Patients with Low Grade Upper Tract Urothelial Cancer Planned at Upcoming Medical Meeting Conference Call to be Held Today at 8:30am ET RA’ANANA, ISRAEL and NEW YORK , March 15, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
